Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1

Phase 2

20%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

Apr 16

SAN.PAPhase 2Phase 2

Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 Phase 2 Results Expected

Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 • Influenza

Drug Information

Target Indication

Influenza

Clinical Trial

Last updated: 12/4/2025